Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) Is a Novel Therapeutic Target in Liposarcoma: A Tissue Microarray Study.

Abstract

BACKGROUND:

Liposarcoma is the most commonly diagnosed subtype of soft tissue sarcoma. As these tumors often arise near vital organs and neurovascular structures, complete resection can be challenging; consequently, recurrence rates are high. Additionally, available chemotherapeutic agents have shown limited benefit and substantial toxicities. There is, therefore, a clear and unmet need for novel therapeutics for liposarcoma. Discoidin domain receptor tyrosine kinase 1 (DDR1) is involved in adhesion, proliferation, differentiation, migration, and metastasis in several cancers. However, the expression and clinical importance of DDR1 in liposarcoma are unknown.

QUESTIONS/PURPOSES:

The purposes of this study were to assess (1) the expression, (2) the association between DDR1 and survival, and (3) the functional roles of DDR1 in liposarcoma.

METHODS:

The correlation between DDR1 expression in tumor tissues and clinicopathological features and survival was assessed via immunohistochemical staining of a liposarcoma tissue microarray. It contained 53 samples from 42 patients with liposarcoma and 11 patients with lipoma. The association between DDR1 and survival in liposarcoma was analyzed by Kaplan-Meier plots and log-rank tests. The DDR1 knockout liposarcoma cell lines were generated by CRISPR-Cas9 technology. The DDR1-specific and highly selective DDR1 inhibitor 7RH was applied to determine the impact of DDR1 expression on liposarcoma cell growth and proliferation. In addition, the effect of DDR1 inhibition on liposarcoma growth was further accessed in a three-dimensional cell culture model to mimic DDR1 effects in vivo.

RESULTS:

The results demonstrate elevated expression of DDR1 in all liposarcoma subtypes relative to benign lipomas. Specifically, high DDR1 expression was seen in 55% (23 of 42) of liposarcomas and no benign lipomas. However, DDR1 expression was not found to be associated with poor survival in patients with liposarcoma. DDR1 knockout or treatment of 7RH showed decreased liposarcoma cell growth and proliferation.

CONCLUSION:

DDR1 is aberrantly expressed in liposarcoma, and it contributes to several markers of oncogenesis in these tumors.

CLINICAL RELEVANCE:

This work supports DDR1 as a promising therapeutic target in liposarcoma.

• Authors: Dylan C Dean, Wenlong Feng, Robert L Walker, Pichaya Thanindratarn, H Thomas Temple, Jonathan C Trent, Andrew E Rosenberg, Francis J Hornicek, Zhenfeng Duan
• Journal: Clinical orthopaedics and related research (Clin Orthop Relat Res) Vol. 481 Issue 11 Pg. 2140-2153 (11 01 2023) ISSN: 1528-1132 [Electronic] United States
• PMID: 37768856 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 by the Association of Bone and Joint Surgeons.

Chemical References

• Discoidin Domain Receptor 1
• DDR1 protein, human

Topics

• Humans
• Discoidin Domain Receptor 1 (genetics, metabolism)
• Cell Proliferation
• Cell Differentiation
• Liposarcoma (drug therapy, genetics)
• Lipoma